title: Beta2-adrenoceptor polymorphisms and obstructive airway diseases: important issues of study design.
abstract: 1. Asthma and chronic obstructive pulmonary disease (COPD) are chronic airway diseases characterized by airflow obstruction. The beta(2)-adrenoceptor mediates bronchodilatation in response to exogenous and endogenous beta-adrenoceptor agonists. 2. Single nucleotide polymorphisms in the beta(2)-adrenoceptor gene (ADRB2) cause amino acid changes (e.g. Arg16Gly, Gln27Glu) that potentially alter receptor function. Recently, a large cohort study found no association between asthma susceptibility and beta(2)-adrenoceptor polymorphisms. In contrast, asthma phenotypes, such as asthma severity and bronchial hyperresponsiveness, have been associated with beta(2)-adrenoceptor polymorphisms. Of importance to asthma management, coding region polymorphisms may alter the response to short-acting and long-acting beta-adrenoceptor agonists, which are commonly prescribed asthma treatments. 3. Optimizing study design would enhance the robustness of genetic association studies of ADRB2 polymorphisms in airway diseases. Characteristics of high-quality studies include suitable study design and subject selection, optimal study of polymorphisms and haplotypes, disease outcomes of relevance, adequate sample size, adjustment for confounding factors, supportive functional data and appropriate analysis, interpretation and replication. Enhancing these study design factors will provide high-quality evidence regarding the biological and clinical importance of beta(2)-adrenoceptor pharmacogenomics in asthma and COPD.
authors: Department of Thoracic Medicine, The Prince Charles Hospital, and School of Medicine, The University of Queensland, Brisbane, Queensland, Australia. ian_yang@health.qld.gov.au
authors: Ian A
authors: IA
authors: Yang
authors: Taria
authors: T
authors: Ng
authors: Peter
authors: P
authors: Molenaar
authors: Kwun M
authors: KM
authors: Fong
mesh_terms: D000402:Airway Obstruction / Q000188:drug therapy* / Q000235:genetics*; D000818:Animals; D006801:Humans; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics*; D012107:Research Design; D018401:Sample Size; D016896:Treatment Outcome
chemical_list: D018343:Receptors, Adrenergic, beta-2